Literature DB >> 20547788

Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.

Thomas Tängdén1, Otto Cars, Asa Melhus, Elisabeth Löwdin.   

Abstract

Foreign travel has been suggested to be a risk factor for the acquisition of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. To our knowledge, this has not previously been demonstrated in a prospective study. Healthy volunteers traveling outside Northern Europe were enrolled. Rectal swabs and data on potential travel-associated risk factors were collected before and after traveling. A total of 105 volunteers were enrolled. Four of them did not complete the study, and one participant carried ESBL-producing Escherichia coli before travel. Twenty-four of 100 participants with negative pretravel samples were colonized with ESBL-producing Escherichia coli after the trip. All strains produced CTX-M enzymes, mostly CTX-M-15, and some coproduced TEM or SHV enzymes. Coresistance to several antibiotic subclasses was common. Travel to India was associated with the highest risk for the acquisition of ESBLs (88%; n = 7). Gastroenteritis during the trip was an additional risk factor (P = 0.003). Five of 21 volunteers who completed the follow-up after 6 months had persistent colonization with ESBLs. This is the first prospective study demonstrating that international travel is a major risk factor for colonization with ESBL-producing Enterobacteriaceae. Considering the high acquisition rate of 24%, it is obvious that global efforts are needed to meet the emergence and spread of CTX-M enzymes and other antimicrobial resistances.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547788      PMCID: PMC2934993          DOI: 10.1128/AAC.00220-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Fecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals.

Authors:  Abdulrahman Abdulla Kader; Angamuthu Kumar; Katapadi Ananthkrishna Kamath
Journal:  Infect Control Hosp Epidemiol       Date:  2007-06-28       Impact factor: 3.254

2.  Community-onset genitourinary tract infection due to CTX-M-15-Producing Escherichia coli among travelers to the Indian subcontinent in New Zealand.

Authors:  Joshua T Freeman; Stephen J McBride; Helen Heffernan; Tracy Bathgate; Chris Pope; Roderick B Ellis-Pegler
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

3.  Short summary of Swedres 2008, a report on antimicrobial utilisation and resistance in humans in Sweden.

Authors:  J Struwe; B Olsson-Liljequist
Journal:  Euro Surveill       Date:  2009-06-25

4.  Duration of stool colonization in patients infected with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Anucha Apisarnthanarak; Thomas C Bailey; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

5.  Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea.

Authors:  Johan Tham; Inga Odenholt; Mats Walder; Alma Brolund; Jonas Ahl; Eva Melander
Journal:  Scand J Infect Dis       Date:  2010-04

6.  Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel.

Authors:  Kevin B Laupland; Deirdre L Church; Jeanne Vidakovich; Melissa Mucenski; Johann D D Pitout
Journal:  J Infect       Date:  2008-11-05       Impact factor: 6.072

7.  Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.

Authors:  K B Laupland; D B Gregson; D L Church; T Ross; J D D Pitout
Journal:  Clin Microbiol Infect       Date:  2008-11       Impact factor: 8.067

8.  Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).

Authors:  Niels Nørskov-Lauritsen; Hélène Marchandin; Michael J Dowzicky
Journal:  Int J Antimicrob Agents       Date:  2009-04-01       Impact factor: 5.283

9.  In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Fernando Baquero; Po-Ren Hsueh; David L Paterson; Flávia Rossi; Grant V Bochicchio; Gale Gallagher; Keith Lantz; Javier Baez Villasenor; Kathleen McCarroll; Murray A Abramson; Joseph W Chow
Journal:  Surg Infect (Larchmt)       Date:  2009-04       Impact factor: 2.150

10.  Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region.

Authors:  Johann D D Pitout; Lorraine Campbell; Deirdre L Church; Daniel B Gregson; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

View more
  114 in total

1.  [Epidemiology of multidrug-resistant organisms in travellers: Results of a 2-year screening in a German level 1 trauma center].

Authors:  J Seifert; M Frank; T Köln; K Beniers; A Kramer; A Ekkernkamp; D Gümbel
Journal:  Unfallchirurg       Date:  2016-03       Impact factor: 1.000

2.  NDM-1 and the Role of Travel in Its Dissemination.

Authors:  Mary Elizabeth Wilson; Lin H Chen
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

3.  CARBapenem utilizatiON evaluation in a large community hospital (CARBON): A Quality Improvement Study.

Authors:  Jesse Janssen; Angus Kinkade; Damen Man
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

Review 4.  Non-prescription antimicrobial use worldwide: a systematic review.

Authors:  Daniel J Morgan; Iruka N Okeke; Ramanan Laxminarayan; Eli N Perencevich; Scott Weisenberg
Journal:  Lancet Infect Dis       Date:  2011-06-12       Impact factor: 25.071

Review 5.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

6.  Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia.

Authors:  Sofia Ny; Roman Kozlov; Uga Dumpis; Petra Edquist; Kirsi Gröndahl-Yli-Hannuksela; Anna-Maria Kling; Danuta O Lis; Christoph Lübbert; Monika Pomorska-Wesołowska; Ivan Palagin; Aija Vilde; Jaana Vuopio; Jan Walter; Karin Tegmark Wisell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-18       Impact factor: 3.267

Review 7.  Travel and the Spread of Drug-Resistant Bacteria.

Authors:  Kevin L Schwartz; Shaun K Morris
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

Review 8.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

10.  The Human Gut Microbiome as a Transporter of Antibiotic Resistance Genes between Continents.

Authors:  Johan Bengtsson-Palme; Martin Angelin; Mikael Huss; Sanela Kjellqvist; Erik Kristiansson; Helena Palmgren; D G Joakim Larsson; Anders Johansson
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.